The disclosed wound-healing formulation adds ingredients from the group consisting of camphor, menthol and eucalyptus to known silver sulfadiazine-based formulations, or to known silver sulfadiazine-and-urogastrone-based formulations, preferably for the topical treatment of skin wounds such as cuts, burns, surgical wounds, etc. Preferred embodiments are in cream form. The disclosed formulation shows unexpected and startling improvement in wound healing rates over expected healing rates using the known silver sulfadiazine-based or silver sulfadiazine-and-urogastrone-based formulations alone.

A system and method of electrotherapy for enhanced drug delivery, comprising an electrode patch and an electrotherapy apparatus providing electrical current onto the electrode patch. The electrode patch contains one or more active drug ingredients in a layer of conductive gel, and the electrotherapy apparatus provides electrical current onto the electrode patch for the enhanced drug delivery of active drug ingredients. The conductive gel is in contact with a human or animal body, and the electrode patch also includes a layer of conductive sheet, a supporting layer, and conductive connectors. The conductive gel has the viscosity allowing it to adhere to skin on a human or animal body. The active drug ingredients that can be delivered through the conductive gel include: lidocaine, capsaicin, menthol, camphor, methyl salicylate, trolamine salicylate, Arnica montana, Calendula officinalis, Hypericum perforatum, Symphytum officinale, cannabidiol (CBD) or any combination of these substances. The mass fraction of the active drug ingredients can vary from 0.001% to 30%. The electrotherapy device can be reused.

Compositions and methods for relieving acute pain, muscular pain, neuropathic pain, and the chronic pain by administering an effective amount of an analgesic composition (preferably formulated as a cream, a gel, a lotion, an ointment, or a salve) including at least: (i) one or more cannabis compounds; (ii) histamine dihydrochloride, salicylate, camphor, menthol, primrose oil, capsaicin, or any of the combination thereof; and optionally, four or more compounds acting as at least antimicrobial preservative(s), antioxidant(s), dispersant(s), emollient(s), emulsifier(s), humectant(s), lubricant(s), penetration enhancer(s), skin conditioner(s), skin protectant(s), thickener(s), or any of the combination thereof to an affected area of a subject in need of pain relief. In a preferred embodiment, the optional third category contributes six or more compounds. Relief of acute and chronic pain without significant deleterious side effects is provided thereby.

Compositions and methods for relieving acute pain, muscular pain, neuropathic pain, and the chronic pain by administering an effective amount of an analgesic composition (preferably formulated as a cream, a gel, a lotion, an ointment, or a salve) including at least: (i) one or more cannabis compounds; (ii) histamine dihydrochloride, salicylate, camphor, menthol, primrose oil, capsaicin, or any of the combination thereof; and optionally, four or more compounds acting as at least antimicrobial preservative(s), antioxidant(s), dispersant(s), emollient(s), emulsifier(s), humectant(s), lubricant(s), penetration enhancer(s), skin conditioner(s), skin protectant(s), thickener(s), or any of the combination thereof to an affected area of a subject in need of pain relief. In a preferred embodiment, the optional third category contributes six or more compounds. Relief of acute and chronic pain without significant deleterious side effects is provided thereby.

The disclosed wound-healing formulation adds ingredients from the group consisting of camphor, menthol and eucalyptus to known silver sulfadiazine-based formulations, or to known silver sulfadiazine-and-urogastrone-based formulations, preferably for the topical treatment of skin wounds such as cuts, burns, surgical wounds, etc. Preferred embodiments are in cream form. The disclosed formulation shows unexpected and startling improvement in wound healing rates over expected healing rates using the known silver sulfadiazine-based or silver sulfadiazine-and-urogastrone-based formulations alone.

The disclosed wound-healing formulation adds ingredients from the group consisting of camphor, menthol and eucalyptus to known silver sulfadiazine-based formulations, or to known silver sulfadiazine-and-urogastrone-based formulations, preferably for the topical treatment of skin wounds such as cuts, burns, surgical wounds, etc. Preferred embodiments are in cream form. The disclosed formulation shows unexpected and startling improvement in wound healing rates over expected healing rates using the known silver sulfadiazine-based or silver sulfadiazine-and-urogastrone-based formulations alone.

Provided herein is a personal care composition that can exhibit an increased vapor release while maintaining physical stability and texture. The personal care composition can contain from about 35% to about 90% petrolatum, from about 20% to about 50% of an olfactory composition, and a gelling agent mixture. The gelling agent mixture can contain dibutyl lauroyl glutamide, dibutyl ethylhexanoyl glutamide, and a solvent selected from the group consisting of pentylene glycol, propylene glycol, hexylene glycol, 3-methyl-1,3-butanediol, 3-methyl-1,2-butanediol, 1,5-pentanediol, and combinations thereof. The personal care composition can exhibit a vapor release of from about 35 mg to about 300 mg at 8 hours and can have an Instability Index of less than about 0.8.

Provided herein is a personal care composition that can exhibit an increased vapor release while maintaining physical stability and texture. The personal care composition can contain from about 35% to about 90% petrolatum, from about 20% to about 50% of an olfactory composition, and a gelling agent mixture. The gelling agent mixture can contain dibutyl lauroyl glutamide, dibutyl ethylhexanoyl glutamide, and a solvent selected from the group consisting of pentylene glycol, propylene glycol, hexylene glycol, 3-methyl-1,3-butanediol, 3-methyl-1,2-butanediol, 1,5-pentanediol, and combinations thereof. The personal care composition can exhibit a vapor release of from about 35 mg to about 300 mg at 8 hours and can have an Instability Index of less than about 0.8.

The present invention provides novel sublingual muco-adhesive cannabinoid compositions in the form of sublingual tablets or films, exhibiting improved bioavailability and stability, reduced side-effects such as irritation, and optionally lower dosage for the same therapeutic effect, in comparison with an alcohol-based oral spray having 5.2 mg of cannabinoid active ingredients per spray.

The present invention provides novel sublingual muco-adhesive cannabinoid compositions in the form of sublingual tablets or films, exhibiting improved bioavailability and stability, reduced side-effects such as irritation, and optionally lower dosage for the same therapeutic effect, in comparison with an alcohol-based oral spray having 5.2 mg of cannabinoid active ingredients per spray.